Abstract: A vehicle control device that: judges a state of a vehicle; structures a plurality of VMs that control equipment installed in the vehicle; and in accordance with the state of the vehicle, switches an order of carrying out activation or stoppage of the plurality of VMs.

Abstract: A vehicle control device includes a re-use determination section and a verification section. When the software of a virtual machine is to be verified, the re-use determination section decides, in accordance with an index assigned beforehand to the virtual machine, whether or not to re-use a verification result of common software that has been obtained in verification of the software of another virtual machine. When the re-use determination section decides to re-use the verification result of the common software obtained in the verification of the software of the other virtual machine, the verification section re-uses the verification result of the common software obtained in the verification of the software of the other virtual machine and verifies VM software of the virtual machine.

Abstract: A vehicle control device acquires a state of the vehicle. Based on the state of the vehicle, the vehicle control device changes processor assignment for a target virtual machine running on a first processor to cause the target virtual machine to run on a second processor. The vehicle control device stops the first processor for which assignment has been changed.

Abstract: A vehicle control device that: judges a state of a vehicle; structures a plurality of VMs that control equipment installed in the vehicle; and in accordance with the state of the vehicle, switches an order of carrying out activation or stoppage of the plurality of VMs.

Abstract: The present invention provides a new compound which has NK1 receptor antagonist activity, whose CYP3A4 inhibitory activity is reduced compared to aprepitant, and which are useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. That is, the present invention relates to carboxymethyl piperidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. Wherein, ring A is a benzene ring or the like; ring B is a pyridine ring or the like; R1 is C1-6 alkyl or C1-6 alkoxy; R2 and R3 are a hydrogen atom or methyl; and n is an integral number from 0 to 5.

Abstract: The present invention provides a new compound which has NK1 receptor antagonist activity, whose CYP3A4 inhibitory activity is reduced compared to aprepitant, and which are useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. That is, the present invention relates to carboxymethyl piperidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. Wherein, ring A is a benzene ring or the like; ring B is a pyridine ring or the like; R1 is C1-6 alkyl or C1-6 alkoxy; R2 and R3 are a hydrogen atom or methyl; and n is an integral number from 0 to 5.

Abstract: Compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. Fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.

Abstract: Compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. Fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.